Adicet Bio Inc.

Adicet Bio, Inc. is a clinical‑stage biotech focused on allogeneic gamma‑delta T‑cell therapies for autoimmune diseases and cancers in the US. Lead pipeline product ADI‑001 (CD20 CAR) is in Phase I for B‑cell NHL; ADI‑270 targets CD70+ solid tumors.

Headquarters: United States (USA)

Website: Visit Site 🔗
Type: Corporation

Company Profile

Sector: Professional Services
Industry: Biotechnology Research

Employees: 152
HQ: Boston

Unlock the full potential.

Get access to Relative P/E Ratio Valuation Histogram.

Upgrade

Traded Instruments

+ Add Instrument 1

Symbol	Name	Type	Exchange	Currency	ISIN	Status	Actions
ACET	Adicet Bio Inc. Cap: 0.1B	EQUITY	NGM	USD	US0070021086	Active	📈